Further comments on the withdrawal of rapacuronium.
D003473:Neuromuscular Nondepolarizing Agents / Q000009:adverse effects*; D013375:Substance Withdrawal Syndrome / Q000503:physiopathology*; D014481:United States; D014486:United States Food and Drug Administration; D014673:Vecuronium Bromide / Q000009:adverse effects* / Q000031:analogs & derivatives*
D003473:Neuromuscular Nondepolarizing Agents; D014673:Vecuronium Bromide; C082938:rapacuronium